Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the following upcoming investor conferences, which are being conducted in a virtual format:

• Oppenheimer 33rd Annual Healthcare Conference: Fireside chat on Tuesday, March 14, 2023, at 8:40am ET
• Stifel 2023 CNS Days: Presentation followed by Q&A on Tuesday, March 28, 2023, at 11:00am ET

A live webcast of both conference events can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events, and will be available for replay for 90 days following the events.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit amylyx.com and follow us on LinkedIn and Twitter. For investors, please visit investors.amylyx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005080/en/

Media
Amylyx Media Team
+1 (857) 799-7274
[email protected]

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
[email protected]

Source: Amylyx Pharmaceuticals, Inc.

You May Also Be Interested In

• Shape Memory Medical Secures $10 Million Financing Led by August Global Partners to Advance Aortic Clinical Programs
• Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
• Zcash Price Prediction: ZEC Eyes $1,000 After 48% Surge as AlphaPepe Emerges in the Top AI Crypto Coin Race